Literature DB >> 15184875

Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma.

Karin Grabmaier1, Mirjam C A de Weijert, Gerald W Verhaegh, Jack A Schalken, Egbert Oosterwijk.   

Abstract

Renal cell carcinoma of the clear cell type (ccRCC) is associated with loss of functional von Hippel-Lindau (VHL) protein and high, homogeneous expression of the G250MN protein, an isoenzyme of the carbonic anhydrase family. High expression of G250MN is found in all ccRCCs, but not in most normal tissues, including normal human kidney. We specifically studied the mechanism of transcriptional regulation of the CAIXG250 gene in RCC. Previous studies identified Sp1 and hypoxia-inducible factor (HIF) as main regulatory transcription factors of G250MN in various non-RCC backgrounds. However, G250MN regulation in RCC has not been studied and may be differently regulated in view of the HIF accumulation under normoxic conditions due to VHL mutations. Transient transfection of different G250MN promoter constructs revealed strong promoter activity in G250MN -positive RCC cell lines, but no activity in G250MN -negative cell lines. DNase-I footprint and band-shift analysis demonstrated that Sp1 and HIF-1alpha proteins in nuclear extracts of RCC cells bind to the CAIX promoter and mutations in the most proximal Sp1 binding element or HIF binding element completely abolished CAIX promoter activity, indicating their critical importance for the activation of G250 expression in RCC. A close correlation between HIF-1alpha expression and G250MN expression was observed. In contrast, no relationship between HIF-2alpha expression and G250MN was seen. The participation of cofactor CBP/p300 in the regulation of G250 transcription was shown. In conclusion, HIF-1alpha and Sp1, in combination with CBP/p300, are crucial elements for G250MN expression in ccRCC, and CAIXG250 can be regarded as a unique HIF-1alpha target gene in ccRCC. Copyright 2004 Nature Publishing Group

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15184875     DOI: 10.1038/sj.onc.1207764

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  73 in total

Review 1.  Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers.

Authors:  Sumanta Kumar Pal; Marcin Kortylewski; Hua Yu; Robert A Figlin
Journal:  Mol Cancer Ther       Date:  2010-11-15       Impact factor: 6.261

2.  [Renal cell carcinoma associated proteins. Isolation, cloning and immunogenicity evaluation].

Authors:  A Haferkamp; M Hohenfellner; R Hautmann; M Zöller
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

3.  Targeted therapy for renal cell carcinoma: a new treatment paradigm.

Authors:  Thomas E Hutson
Journal:  Proc (Bayl Univ Med Cent)       Date:  2007-07

Review 4.  Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show?

Authors:  Stefan Kaluz; Milota Kaluzová; Shu-Yuan Liao; Michael Lerman; Eric J Stanbridge
Journal:  Biochim Biophys Acta       Date:  2009-01-22

Review 5.  G250: a carbonic anhydrase IX monoclonal antibody.

Authors:  John S Lam; Allan J Pantuck; Arie S Belldegrun; Robert A Figlin
Journal:  Curr Oncol Rep       Date:  2005-03       Impact factor: 5.075

Review 6.  Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma.

Authors:  Pierre Combe; Eleonore de Guillebon; Constance Thibault; Clémence Granier; Eric Tartour; Stéphane Oudard
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

7.  Stabilization of HIF-1alpha is critical to improve wound healing in diabetic mice.

Authors:  Ileana Ruxandra Botusan; Vivekananda Gupta Sunkari; Octavian Savu; Anca Irinel Catrina; Jacob Grünler; Stina Lindberg; Teresa Pereira; Seppo Ylä-Herttuala; Lorenz Poellinger; Kerstin Brismar; Sergiu-Bogdan Catrina
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-04       Impact factor: 11.205

8.  Molecular targeting of carbonic anhydrase IX in mice with hypoxic HT29 colorectal tumor xenografts.

Authors:  Sean Carlin; Nahida Khan; Thomas Ku; Valerie A Longo; Steve M Larson; Peter M Smith-Jones
Journal:  PLoS One       Date:  2010-05-27       Impact factor: 3.240

9.  Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology.

Authors:  Chen Xu; Agnes Lo; Anuradha Yammanuru; Aimee St Clair Tallarico; Kristen Brady; Akikazu Murakami; Natasha Barteneva; Quan Zhu; Wayne A Marasco
Journal:  PLoS One       Date:  2010-03-10       Impact factor: 3.240

10.  The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy.

Authors:  E Y Tan; M Yan; L Campo; C Han; E Takano; H Turley; I Candiloro; F Pezzella; K C Gatter; E K A Millar; S A O'Toole; C M McNeil; P Crea; D Segara; R L Sutherland; A L Harris; S B Fox
Journal:  Br J Cancer       Date:  2009-01-27       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.